The Technical Analyst
Centogene NV [CNTG]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Centogene NV Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.96% €0.461
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 12.85 mill |
| EPS: | -1.550 |
| P/E: | -0.300 |
| Earnings Date: | May 14, 2024 |
| SharesOutstanding: | 27.87 mill |
| Avg Daily Volume: | 0.0596 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | n/a | n/a | ||||
| Asset | n/a | n/a | ||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.300 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ 0.376 - 0.546 ( +/- 18.44%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - €0.475
Forecast 2: 16:00 - €0.475
Forecast 3: 16:00 - €0.475
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €0.461 (-3.96% ) |
| Volume | 0.0193 mill |
| Avg. Vol. | 0.0596 mill |
| % of Avg. Vol | 32.43 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CNTG
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CNTG
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Latest Press Releases
2024-04-02 16:30:00 - Press Release
Centogene Receives Nasdaq Non-compliance Notice
Cambridge, mass. and rostock, germany and berlin, april 02, 2024 (globe newswire) -- centogene n.v. (nasdaq: cntg) (“centogene”, “we”, or the “company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated march 27, 2024, from the nasdaq stock market llc listing qualifications department, indicating that the company was not in compliance with the minimum bid price requirement set forth in rule 5450(a)(1) of the nasdaq listing rules since the closing bid price for the company's common shares listed on nasdaq was below us$1.00 for 30 consecutive business days (from february 12 through march 26, 2024)...
2024-03-19 06:30:00 - Press Release
Centogene Extends Strategic Partnership With Takeda To Continue Providing Access To Genetic Testing For Patients With Lysosomal Storage Disorders
Cambridge, mass. and rostock, germany and berlin, march 19, 2024 (globe newswire) -- centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with takeda (tse: 4502/nyse: tak) to diagnose patients with lysosomal storage disorders (lsds).
2024-02-29 17:00:00 - Press Release
Centogene Collaborates On Research Published In Science Showing Immunopathological Landscape Of Human Pre-tcrΑ Deficiency
Complete pre-tcrΑ deficiency found to be very rare, partial form more common than expected complete pre-tcrΑ deficiency found to be very rare, partial form more common than expected
2024-02-28 06:30:00 - Press Release
Centogene Announces Receipt Of Nasdaq Notice Of Delisting And Intention To Request A Hearing
Notice of delisting will not immediately result in the suspension or delisting of the company's securities notice of delisting will not immediately result in the suspension or delisting of the company's securities
2024-02-28 06:30:00 - Press Release
Centogene Explores Strategic Alternatives
Cambridge, mass. and rostock, germany and berlin, feb. 28, 2024 (globe newswire) -- centogene n.v. (nasdaq: cntg) (the “company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that the company has decided to explore a range of strategic alternatives focused on sustainable long-term value creation for the benefit of its stakeholders.
Latest News
2023-09-01 08:29:00 - Market Watch
Centogene shares climb after study confirms biomarker for Gaucher disease
Shares of Centogene NV CNTG, +8.31% gained 7% premarket on Friday after the company announced data confirming the utility of its proprietary biomarker lyso-Gb1 in indicating the severity of Gaucher disease, a rare inherited disorder that affects the body's ability to break down a certain type of fat. The study results also indicate that lyso-Gb1 could help predict the clinical course of patients and personalize care for the disease, Centogene said in a release.
2023-08-07 06:30:00 - GlobeNewsWire
CENTOGENE to Participate in Upcoming Conferences in August
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for August 2023. CENTOGENE representatives are attending events in Brazil and Switzerland, and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.
2023-06-27 08:54:00 - Market Watch
Centogene shares jump on joint venture with Lifera
Shares of Centogene NV CNTG, -2.20%, which specializes in genetic diagnostics for rare diseases, jumped 50% in premarket trading Tuesday after the company announced a joint venture with Lifera, a biopharmaceutical company owned by Saudia Arabia's Public Investment Fund. The JV brings Centogene a $30 million investment and will focus on providing multiomic testing to patients, health systems, biopharma clients and research institutions in Saudia Arabia and countries of the Gulf Cooperation Council, the company said in a release.
2023-05-05 06:30:00 - GlobeNewsWire
CENTOGENE to Participate in Upcoming Conferences in May
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for May 2023. CENTOGENE representatives are attending events in Brazil, the U.S., and Germany, as well as virtually, and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.
2023-04-14 08:00:00 - GlobeNewsWire
CENTOGENE to Participate in Upcoming Conferences in April
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for April 2023. CENTOGENE representatives will be attending events in Spain, the U.S., and Germany and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.
2023-03-08 06:30:00 - GlobeNewsWire
CENTOGENE to Participate in Upcoming Conferences in March
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 08, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for March 2023. CENTOGENE representatives will be attending events in Brazil, the U.S., Saudi Arabia, Thailand, and the U.K. and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.
2023-02-07 06:30:00 - GlobeNewsWire
CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its partnering conference schedule for February 2023, with a focus on rare and genetic diseases in the lead up to Rare Disease Day (RDD) on February 28th. Since 2008, RDD has been held annually on the last day of February and includes a range of activities and initiatives throughout the month. Bringing together physicians, patient organizations, researchers, medical companies, and of course, rare disease patients from around the world, RDD raises awareness and generates change for the rare disease community.
2022-12-01 06:30:00 - GlobeNewsWire
CENTOGENE to Participate in Upcoming Conferences in December
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for December 2022. The Company's Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Japan. CENTOGENE invites attendees to schedule one-on-one meetings.
2022-11-10 06:30:00 - GlobeNewsWire
CENTOGENE to Participate in Upcoming Conferences in November
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for November 2022. The Company's Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Spain. CENTOGENE invites attendees to schedule one-on-one meetings.
2022-09-01 06:30:00 - GlobeNewsWire
CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced its investment and partnering conference schedule for September 2022. Company management will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York and the 9th Annual HealthTech Investment Forum (HTIF) as part of Sachs Autumn Life Sciences Week in Basel. CENTOGENE invites investors and partners to attend the presentations and schedule one-on-one meetings.